Pàgina inicial > Resultats de la cerca: Holgado, Esther
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 3 registres trobats en 0.03 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
15 p, 1.4 MB Critical role of interleukin (IL)-17 in inflammatory and immune disorders : An updated review of the evidence focusing in controversies / Ruiz de Morales, José María G. (Universidad de León) ; Puig, Lluís (Universitat Autònoma de Barcelona. Departament de Medicina) ; Daudén, Esteban (Hospital Universitario de la Princesa (Madrid)) ; Cañete, Juan D. (Hospital Clínic i Provincial de Barcelona) ; Pablos, José Luis (Hospital Universitario 12 de Octubre (Madrid)) ; Martín, Antonio Oliveira (Hospital Universitario La Paz (Madrid)) ; Juanatey, Carlos González (Hospital Universitario Lucus Augusti (Lugo)) ; Adan Civera, Alfredo (Hospital Clínic i Provincial de Barcelona) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Borruel, Natalia (Hospital Universitari Vall d'Hebron) ; Ortí, Guillermo (Vall d'Hebron Institut d'Oncologia) ; Holgado-Martín, Esther (Ruber Internacional) ; Garcia-Vidal, Carolina (Hospital Clínic i Provincial de Barcelona) ; Vizcaya-Morales, Cynthia (Novartis Pharma) ; Martín-Vázquez, Víctor (Novartis Farmacéutica) ; González-Gay, Miguel Ángel (Universidad de Cantabria)
Interleukin 17 (IL-17) is a proinflammatory cytokine that has been the focus of intensive research because of its crucial role in the pathogenesis of different diseases across many medical specialties. [...]
2020 - 10.1016/j.autrev.2019.102429
Autoimmunity Reviews, Vol. 19 Núm. 1 (january 2020) , p. 102429  
Registre complet - Creative Commons
2.
14 p, 1.4 MB Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer : a pilot clinical trial / Quintela-Fandino, Miguel (Hospital Universitario Quiron. Medical Oncology Department) ; Holgado, Esther (Hospital Universitario Ramón y Cajal (Madrid)) ; Manso, Luis (Hospital Universitario 12 de Octubre (Madrid)) ; Morales, Serafin (Hospital Arnau de Vilanova (València)) ; Bermejo, Begoña (Centro de Investigación Biomédica en Red de Cáncer) ; Colomer, Ramon (Universidad Autónoma de Madrid. Facultad de Medicina) ; Apala, Juan V. (Hospital Universitario de Fuenlabrada ( Madrid)) ; Blanco, Raquel (Centro Nacional de Biotecnología/CSIC. Department of Immunology and Oncology) ; Muñoz, Manuel (Breast Cancer Clinical Research Unit - Clinical Research Program, CNIO - Spanish National Cancer Research Center) ; Caleiras, Eduardo (Histopathology Core Unit - Biotechnology Program, CNIO - Spanish National Cancer Research Center) ; Iranzo, Vega (Universitat de València. Departament de Medicina) ; Martínez López, Mario (Hospital Universitario 12 de Octubre (Madrid)) ; Dominguez, Orlando (Genomics Core Unit - Biotechnology Program, CNIO - Spanish National Cancer Research Center) ; Hornedo, Javier (Hospital Universitario Quiron. Medical Oncology Department) ; Gonzalez-Cortijo, Lucia (Hospital Universitario Quiron. Medical Oncology Department) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Gasol Cudos, Ariadna (Hospital Arnau de Vilanova (València)) ; Malon, Diego (Hospital Universitario de Fuenlabrada ( Madrid)) ; Lopez-Alonso, Antonio (Spanish National Cancer Research Center) ; Moreno-Ortíz, María C. (Centro Nacional de Biotecnología/CSIC) ; Mouron, Silvana (Spanish National Cancer Research Center) ; Mañes, Santos (Centro Nacional de Biotecnología/CSIC) ; Universitat Autònoma de Barcelona
Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explore the efficacy and biomarkers of combining the anti-PD-L1 durvalumab plus the antiangiogenic bevacizumab after bevacizumab monotherapy for advanced HER2-negative breast cancer. [...]
2020 - 10.1186/s13058-020-01362-y
Breast cancer research, Vol. 22 (november 2020)  
Registre complet - Creative Commons
3.
9 p, 1.7 MB Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design / Sampayo-Cordero, Miguel (Medica Scientia Innovation Research (MedSIR)) ; Miguel-Huguet, Bernat (Hospital Universitari de Bellvitge) ; Pérez-García, José (QuironSalud Group) ; Páez, David (Institut d'Investigació Biomèdica Sant Pau) ; Guerrero-Zotano, Ángel L. (Vanderbilt University Medical Center) ; Garde-Noguera, Javier (Hospital Arnau de Vilanova (Lleida, Catalunya)) ; Aguirre, Elena (Hospital Quirónsalud Zaragoza) ; Holgado, Esther (Hospital Universitario Ramón y Cajal (Madrid)) ; López-Miranda, Elena (Hospital Universitario Ramón y Cajal (Madrid)) ; Huang, Xin (Pfizer Global Research and Development) ; Malfettone, Andrea (Medica Scientia Innovation Research (MedSIR)) ; Llombart-Cussac, Antonio (Hospital Arnau de Vilanova (Lleida, Catalunya)) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
Non-inferiority (NI) analysis is not usually considered in the early phases of clinical development. In some negative phase II trials, a post-hoc NI analysis justified additional phase III trials that were successful. [...]
2020 - 10.1016/j.conctc.2020.100678
Contemporary Clinical Trials Communications, Vol. 20 (november 2020)  
Registre complet - Creative Commons

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem